Browse by author
Lookup NU author(s): Professor Camille CarrollORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2024 International Parkinson and Movement Disorder Society. Traditional drug development in Parkinson's disease (PD) faces significant challenges because of its protracted timeline and high costs. In response, innovative master protocols are emerging and designed to address multiple research questions within a single overarching protocol. These trials may offer advantages such as increased efficiency, agility in adding new treatment arms, and potential cost savings. However, they also present organizational, methodological, funding, regulatory, and sponsorship challenges. We review the potential of master protocols, focusing on platform trials, for disease modifying therapies in PD. These trials share a common control group and allow for the termination or addition of treatment arms during a trial with non-predetermined end. Specific issues exist for a platform trial in the PD field considering the heterogeneity of patients in terms of phenotype, genotype and staging, the confounding effects of symptomatic treatments, and the choice of outcome measures with no consensus on a non-clinical biomarker to serve as a surrogate and the slowness of PD progression. We illustrate these aspects using the examples of the main PD platform trials currently in development with each one targeting distinct goals, populations, and outcomes. Overall, platform trials hold promise in expediting the evaluation of potential therapies for PD. However, it remains to be proven whether these theoretical benefits will translate into increased production of high-quality trial data. Success also depends on the willingness of pharmaceutical companies to engage in such trials and whether this approach will ultimately hasten the identification and licensing of effective disease-modifying drugs. © 2024 International Parkinson and Movement Disorder Society.
Author(s): Fabbri M, Rascol O, Foltynie T, Carroll C, Postuma RB, Porcher R, Corvol JC
Publication type: Article
Publication status: Published
Journal: Movement Disorders
Year: 2024
Volume: 39
Issue: 9
Pages: 1468-1477
Print publication date: 01/09/2024
Online publication date: 26/06/2024
Acceptance date: 03/06/2024
ISSN (print): 0885-3185
ISSN (electronic): 1531-8257
Publisher: John Wiley and Sons Inc.
URL: https://doi.org/10.1002/mds.29899
DOI: 10.1002/mds.29899
PubMed id: 38925541
Altmetrics provided by Altmetric
